U.S. Launches New Strikes on Iran as Trump Signals Peace Deal Uncertainty 
NHS shakeup: if it sounds like we’ve been here before, it’s because we have 
RBNZ Holds Interest Rates Steady but Signals More Hikes Ahead in 2026 
NIO CEO Says China’s Auto Industry Has Passed Its Golden Era Amid Weak Car Sales 
Gold Prices Edge Higher as Markets Monitor U.S.-Iran Peace Talks 
Australia Sues 3M for Over A$2 Billion Over PFAS Firefighting Foam Contamination 
U.S. Sanctions Iran’s Strait of Hormuz Authority as Global Oil Markets Face Turmoil 
Wall Street Climbs as Micron Leads Chip Stock Rally Amid Iran Peace Hopes 
Australia Urged to Simplify Regulations to Revive IPO Market and Boost Innovation 
Uruguay Central Bank Holds Interest Rate at 5.75% Amid Inflation and Oil Price Concerns 
Morgan Stanley Names Top AI Security and Data Center Stocks for 2026 
EU Antitrust Probe Could Lead to Massive Google Fine Under DMA Rules 
Toshifumi Suzuki, Founder of Seven-Eleven Japan, Dies at 93 
Ferrari Luce: How Ferrari Evolved From Hybrid Supercars to Its First Fully Electric Vehicle 
Boeing Wins Fraud Lawsuit Over 737 MAX Filed by LOT Polish Airlines 
UK Grocery Inflation Slows to 3.1% as Supermarket Price Pressures Ease in May 2026 
Oil Prices Jump After New U.S. Strikes on Iran Raise Supply Concerns 
Moderna has assigned its new chief medical officer after recruiting a former Johnson & Johnson executive. It was reported that effective on July 6, Dr. Paul Burton will be joining the American pharmaceutical and biotechnology company based in Cambridge, Massachusetts.
As per Market Watch, Dr. Burton worked in Janssen Pharmaceuticals as its chief global medical affairs officer from March 2020, but he has been with Johnson & Johnson for 16 years and held various executive positions during his tenure.
Burton moves to Moderna
Dr. Paul Burton will be replacing Tal Zaks, who is said to be leaving Moderna after six years with the company. The incoming Moderna medical chief was also said to have previously worked as the vice president and head of cardiovascular and metabolic medical affairs in J&J.
He will be joining the biotech firm at the time when it is seeking approval from the government’s health regulators so that its COVID-19 vaccine could be used for adolescents too. Moderna’s chief executive officer, Stephane Bancel, said that testing results for the use of the vaccine in children will be available by fall. If the outcome is good, she said that it could help get a nod from the regulators and health safety boards.
“Paul’s extensive medical experience in the global pharmaceutical and biotech industry will be important to Moderna as we expand internationally and continue our journey as a commercial company,” CEO Bancel said in a press release. “As we work to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients, Paul’s expertise across multiple therapeutic areas and his proven track record leveraging data science and digital technologies to reimagine medical engagement will be invaluable.”
Moderna’s foray into COVID-19 vaccine production
Moderna’s name became popular after joining the list of pharmaceutical firms that develop and produce vaccines for COVID-19. Its label was often in the headlines since last year, and now it is considered as one of the leading suppliers of vaccines worldwide.
Moderna’s CEO believes that with Dr. Paul Burton’s expertise, the company will achieve more of its goals in the coming years. She said that she is really looking forward to working with the new medical chief as they could achieve many things together.
